Abstract
Background Salmonella enterica serovar Paratyphi A (Salmonella Paratyphi A) is the primary causative agent of paratyphoid fever, which is responsible for an estimated 3.4 million infections annually. However, little genomic information is available on population structure, antimicrobial resistance (AMR), and spatiotemporal distribution of the pathogen. With rising antimicrobial resistance and no licensed vaccines, genomic surveillance is important to track the evolution of this pathogen and monitor transmission.
Results We performed whole-genome sequencing of 817 Salmonella Paratyphi A isolates collected from Bangladesh, Nepal, and Pakistan and added publicly available 562 genomes to build a global database representing 37 countries, covering 1917-2019. To track the evolution of Salmonella Paratyphi A, we used the existing lineage scheme, developed earlier based on a small dataset, but certain sub-lineages were not homologous, and many isolates could not be assigned a lineage. Therefore, we developed a single nucleotide polymorphism based genotyping scheme, Paratype, a tool that segregates Salmonella Paratyphi A into three primary and nine secondary clades, and 18 genotypes. Each genotype has been assigned a unique allele definition located on a conserved gene. Using Paratype, we identified genomic variation between different sampling locations and specific AMR markers, and mutations in the O2-polysaccharide synthesis locus, a candidate for vaccine development.
Conclusions This large-scale global analysis proposes the first genotyping tool for Salmonella Paratyphi A. Paratype has already been released (https://github.com/CHRF-Genomics/Paratype) as an open-access, command-line tool and is being adopted for large scale genomic analysis. This tool will assist future genomic surveillance and help inform prevention and treatment strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was partially funded by the Bill and Melinda Gates Foundation (grant numbers INV-023821 and INV-008335).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the parent studies were obtained from the Bangladesh Institute of Child Health Ethical Review Committee, Nepal Health Research Council, Aga Khan University Hospital Ethics Committee and Pakistan National Ethics Committee, Stanford University Institutional Review Board, and U.S. Centers for Disease Control and Prevention. Informed written consent and clinical information were taken from adult participants and legal guardians of child participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
arif.tanmoy{at}chrfbd.org, yhooda{at}chrfbd.org, saiful.sajib{at}chrfbd.org, samir{at}chrfbd.org, senjutisaha{at}chrfbd.org, kesiaeds{at}stanford.edu, sluby{at}stanford.edu, jandr{at}stanford.edu, junaid.iqbal{at}aku.edu, farah.qamar{at}aku.edu, gd312{at}medschl.cam.ac.uk, sgb47{at}medschl.cam.ac.uk, Zoe.Dyson{at}lshtm.ac.uk, Denise.Garrett{at}Sabin.org
Figure 4 revised
Data Availability
All data produced in the present work are contained in the manuscript
